National Crisis Supercedes Coverage Debate
PBMs: Merck-Medco in the Hot Seat
AIDS Treatments: Discounts Here to Stay
Chaotic Content: Streamlined Solutions
Clinical Trial: FDA Stays Silent on Trovan Charges
National Crisis Supercedes Coverage Debate
A Five-Year Forecast: Clear Seas Ahead?
Weak Bones, Strong Market
Approvals: Novartis’ Silver Lining
Pfizer and others Pitch In
Oncology: EMEA Approval Lags
BioTech's New Business Model
Also Known As...The Value of Generic Names
Health Plan Premiums: Pharma Takes the Blame